<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01715935</url>
  </required_header>
  <id_info>
    <org_study_id>2011-000882-11</org_study_id>
    <nct_id>NCT01715935</nct_id>
  </id_info>
  <brief_title>Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus</brief_title>
  <acronym>NEORAD</acronym>
  <official_title>A Comparison of Blood and Tissue Biomarkers Before and After Nephrectomy in the First-line Setting With Everolimus in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Disease and Stage: Metastatic and locally advanced clear cell renal carcinoma&#xD;
&#xD;
      An open-label, exploratory, single-arm, multicenter trial.&#xD;
&#xD;
      Everolimus will be administered orally, once daily, for 6 weeks followed by a 1-week rest&#xD;
      period prior to nephrectomy.&#xD;
&#xD;
      Two to four weeks after surgery, everolimus will be reintroduced only for metastatic patients&#xD;
      until disease progression, unacceptable toxicity, withdrawal of patient consent, or other&#xD;
      stopping rules are met.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An open-label, exploratory, single-arm, multicenter trial. Treatment with everolimus will be&#xD;
      initiated once patients have undergone baseline screening and provided their written informed&#xD;
      consent.&#xD;
&#xD;
      Everolimus will be administered orally, once daily, for 6 weeks followed by a 1-week rest&#xD;
      period prior to surgery. The starting dose will be 10 mg daily with provision for dose&#xD;
      reduction based on tolerability.&#xD;
&#xD;
      Radical nephrectomy will be performed at the end of week 7. For metastatic patients, two to&#xD;
      four weeks after surgery, everolimus will be reintroduced. Treatment will be continued until&#xD;
      disease progression, unacceptable toxicity, withdrawal of patient consent, or other stopping&#xD;
      rules are met.&#xD;
&#xD;
      Patients with locally advanced renal carcinoma will stop drug intake before nephrectomy.&#xD;
&#xD;
      Resumption of everolimus may be postponed in cases of a delay in wound healing or surgical&#xD;
      complications.&#xD;
&#xD;
      After treatment discontinuation and the last treatment visit (28-days after the last dose),&#xD;
      patients will be followed up in order to collect data on the onset of progression and&#xD;
      survival. In metastatic patients discontinuing treatment for reasons other than disease&#xD;
      progression, tumor assessment will continue every 3 months, until disease progression or&#xD;
      initiation of other anticancer therapy for up to one year of follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective clinical benefit</measure>
    <time_frame>After 6 weeks of treatment</time_frame>
    <description>Objective clinical benefit is defined as complete response, partial response or stable disease according to RECIST criteria version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>Participants will be followed all along the treatment period, an expected average of 15 months</time_frame>
    <description>Toxicity will be classify according to NCI-CTC criteria Version 4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Clear-cell Renal Carcinoma</condition>
  <condition>Clear-cell Metastatic Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)</description>
    <arm_group_label>everolimus</arm_group_label>
    <other_name>AFINITOR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced RCC or a resectable renal tumor and at least one measurable inoperable&#xD;
             metastasis (at least 1 cm), in whom anti-angiogenic therapy is indicated&#xD;
&#xD;
          -  Patients without target lesions, with bone metastasis&#xD;
&#xD;
          -  Histologically confirmed clear cells RCC and possibility of adequate tumor sampling&#xD;
             prior to treatment&#xD;
&#xD;
          -  No prior systemic treatment for RCC&#xD;
&#xD;
          -  Male or female, at least 18 years&#xD;
&#xD;
          -  PS ECOG 0-1&#xD;
&#xD;
          -  Life expectancy at least 3 months&#xD;
&#xD;
          -  Adequate organ function with the following criteria:&#xD;
&#xD;
               -  Total serum bilirubin equal or less than 2 x ULN (Gilbert's disease exempted)&#xD;
&#xD;
               -  Serum transaminases and alkaline phosphatases equal or less than 2.5 x ULN, or in&#xD;
                  case of liver or bone metastasis equal or less than 5x ULN&#xD;
&#xD;
               -  Serum creatinine equal or less than 2 x ULN, creatinine clearance at least 50&#xD;
                  ml/min&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) at least 1500/mm3&#xD;
&#xD;
               -  Platelets at least 100,000/mm3&#xD;
&#xD;
               -  Hemoglobin at least 10.0 g/dL&#xD;
&#xD;
               -  INR equal or less than 1.7 or prothrombin time (PT) equal or less than 6 sec&#xD;
&#xD;
               -  Blood glucose less than 1.5x ULN&#xD;
&#xD;
               -  Fasting cholesterol equal or less than 5 mmol/L, triglycerides equal or less than&#xD;
                  200 mg/dl,&#xD;
&#xD;
          -  Negative pregnancy test within 7 days prior to enrollment&#xD;
&#xD;
          -  Signed and dated IRB/ICE-approved informed consent form&#xD;
&#xD;
          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests and other study procedures.&#xD;
&#xD;
          -  Patient covered by the national health system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous nephrectomy&#xD;
&#xD;
          -  Histology: any histologic type different than ccRCC&#xD;
&#xD;
          -  Treatment in a clinical trial in the last 30 days&#xD;
&#xD;
          -  Previous treatment with everolimus or other mTOR-inhibitors and anti-angiogenic drugs&#xD;
&#xD;
          -  Any of the following within 12 months prior to treatment initiation: severe/unstable&#xD;
             angina, myocardial infarction, coronary artery bypass graft, symptomatic congestive&#xD;
             heart failure, ischemic or hemorrhagic stroke including transient ischemic attack,&#xD;
             abnormal lung function.&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure &gt;150 mmHg or diastolic&#xD;
             pressure &gt;90 mmHg, despite optimal medical treatment&#xD;
&#xD;
          -  Abnormal ECG (Clinically significant)&#xD;
&#xD;
          -  Treatment with vitamin K antagonists. Ongoing treatment with therapeutic doses of&#xD;
             coumarin derivative anticoagulants (e.g. warfarin) or treatment within the 2 weeks&#xD;
             before the first day of everolimus administration. Prophylaxis with low dose warfarin&#xD;
             for deep vein thrombosis is permitted (up to 2 mg/day). Low molecular weight heparin&#xD;
             is allowed.&#xD;
&#xD;
          -  Brain metastasis. (Brain scan or MRI is mandatory). Note: Previous treated brain&#xD;
             metastasis (surgery ± radiotherapy, radiotherapy, radiosurgery or gammaknife) and&#xD;
             satisfying the following three criteria are allowed:&#xD;
&#xD;
               -  Asymptomatic;&#xD;
&#xD;
               -  No evidence of any active brain metastasis 3 months prior inclusion;&#xD;
&#xD;
               -  No necessity of corticoid or antiepileptic treatment.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Any second malignancy within the last 3 years with the exception of basal cell&#xD;
             carcinoma, in situ cervical cancer and pT1/a bladder cancer with no evidence of&#xD;
             recurrent disease for 12 months.&#xD;
&#xD;
          -  Clinically significant gastrointestinal abnormalities including but not limited to:&#xD;
&#xD;
               -  Malabsorption syndrome&#xD;
&#xD;
               -  Major resection of the stomach or small bowel that could affect the absorption of&#xD;
                  the study drug&#xD;
&#xD;
               -  Active peptic ulcer disease&#xD;
&#xD;
               -  Inflammatory bowel disease&#xD;
&#xD;
               -  Ulcerative colitis or other gastrointestinal conditions with increased risk of&#xD;
                  perforation&#xD;
&#xD;
               -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal&#xD;
                  abscess within 28 days prior to beginning study treatment&#xD;
&#xD;
               -  Hepatitis B/C&#xD;
&#xD;
          -  Hypersensitivity to everolimus or any excipient of everolimus.&#xD;
&#xD;
          -  Any active (acute or chronic) or uncontrolled infection/disorders that impair the&#xD;
             ability to evaluate the patient or for the patient to complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane Oudard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Européen Georges Pompidou, Paris (France)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Départemental Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925 cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Eloi - CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34285 cedex 5</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fôpital d'Instruction des Amées du Val de Grâce</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Européen Georges Pompidou - Service d'oncologie médicale</name>
      <address>
        <city>Paris</city>
        <zip>7505</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre-lès-nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805 cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>October 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2012</study_first_posted>
  <last_update_submitted>August 18, 2016</last_update_submitted>
  <last_update_submitted_qc>August 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Clear cells renal carcinoma</keyword>
  <keyword>everolimus</keyword>
  <keyword>neo-adjuvant treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

